ArticleAtherosclerosis2018
Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study.
Article in Atherosclerosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07654231 (Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD), which is not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Association between fibroblast growth factor 23 and coronary artery calcification in patients with chronic kidney disease: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Role of klotho and fibroblast growth factor 23 in arterial calcification, thickness, and stiffness: a meta-analysis of observational studies.Scientific reports · 2024Pooled it
- Pooled it
- A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.Journal of the American Society of Nephrology : JASN · 2019Trial
- A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD.Journal of the American Society of Nephrology : JASN · 2019Trial
- Calcified coronary artery disease: Mechanisms, risk factors and clinical consequences.World journal of biological chemistry · 2026Review
- Phosphate homeostasis and apparent treatment-resistant hypertension in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Coronary Artery Calcification: From Molecular Mechanisms to Interventional Strategies.International journal of molecular sciences · 2026Review
- Associations of Central Adiposity With Subclinical Coronary Calcification and Disease Progression: Meta-Analysis of 68,629 Participants.JACC. Advances · 2026Article
- Preheparin Serum Lipoprotein Lipase Mass as a Coronary Risk Factor in Patients With Chronic Kidney Disease.Cardiology research · 2026Article
- Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies.Frontiers in pharmacology · 2026Review
- Does Atherosclerosis Progress Faster After Liver Transplant? A Comparative Study and Analysis of Progression Risk Factors.Journal of transplantation · 2026Article
- Article
- Undiagnosed Coronary Artery Disease in Hemodialysis-Initiating Patients.Journal of atherosclerosis and thrombosis · 2025Article
- Use of Calcium Modification in Percutaneous Coronary Intervention: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Risk factors for coronary artery disease progression: A retrospective cohort study of clinical and biochemical predictors.Medicine · 2025Observational
- The Prognostic Impact of Kidney Dysfunction in Unselected Patients Undergoing Coronary Angiography: In What Subgroups Does Kidney Dysfunction Matter?Journal of clinical medicine · 2025Article
- Progression of Carotid Intima-Media Thickness in Children of the Cardiovascular Comorbidity in Children With Chronic Kidney Disease Study: Risk Factors and Impact of Blood Pressure Dynamics.Journal of the American Heart Association · 2025Article
- Asymmetric Dimethylarginine (ADMA) as a Novel Risk Factor for Progression of Coronary Artery Calcification in Patients with Chronic Kidney Disease.Journal of clinical medicine · 2025Article
- Progression of Coronary Artery Calcification and Risk of Clinical Events in CKD: The Chronic Renal Insufficiency Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsCoronary artery calcification (CAC) is common among patients with chronic kidney disease (CKD) and predicts the risk for cardiovascular disease (CVD). We examined the associations of novel risk factors with CAC progression among patients with CKD.
methodsAmong 1123 CKD patients in the Chronic Renal Insufficiency Cohort (CRIC) Study, CAC was measured in Agatston units at baseline and a follow-up visit using electron beam computed tomography or multidetector computed tomography.
resultsOver an average 3.3-year follow-up, 109 (25.1%) participants without CAC at baseline had incident CAC and 124 (18.0%) participants with CAC at baseline had CAC progression, defined as an annual increase of ≥100 Agatston units. After adjustment for established atherosclerotic risk factors, several novel risk factors were associated with changes in CAC over follow-up. Changes in square root transformed CAC score associated with 1 SD greater level of risk factors were -0.20 (95% confidence interval, -0.31 to -0.10; p < 0.001) for estimated glomerular filtration rate, 0.14 (0.02-0.25; p = 0.02) for 24-h urine albumin, 0.25 (0.15-0.34; p < 0.001) for cystatin C, -0.17 (-0.27 to -0.07; p < 0.001) for serum calcium, 0.14 (0.03-0.24; p = 0.009) for serum phosphate, 0.24 (0.14-0.33; p < 0.001) for fibroblast growth factor-23, 0.13 (0.04-0.23; p = 0.007) for total parathyroid hormone, 0.17 (0.07-0.27; p < 0.001) for interleukin-6, and 0.12 (0.02-0.22; p = 0.02) for tumor necrosis factor-α.
conclusionsReduced kidney function, calcium and phosphate metabolism disorders, and inflammation, independent of established CVD risk factors, may progress CAC among CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.